Global Leading Market Research Publisher QYResearch announces the release of its latest report “Influenza A-B Virus Detection Kit – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Influenza A-B Virus Detection Kit market, including market size, share, demand, industry development status, and forecasts for the next few years.
For infectious disease diagnostics executives, public health officials, and healthcare investors, accurate and timely influenza testing is a cornerstone of respiratory infection management. Seasonal influenza affects an estimated 1 billion people annually worldwide, causing 3–5 million severe cases and 290,000–650,000 respiratory deaths. Rapid differentiation between influenza A, influenza B, and other respiratory pathogens (SARS-CoV-2, RSV) enables appropriate antiviral therapy, reduces unnecessary antibiotic use, and informs public health surveillance. The Influenza A-B Virus Detection Kit is an in vitro diagnostic product designed to detect Influenza A and B virus antigens or nucleic acids from respiratory specimens, utilizing immunochromatographic assays (lateral flow), fluorescent immunoassays, or real-time quantitative PCR technology, suitable for hospital laboratories, public health institutions, and home testing scenarios. The global market for Influenza A-B Virus Detection Kit was estimated to be worth USD 1,530 million in 2024 and is forecast to reach USD 2,148 million by 2031, growing at a CAGR of 4.9% from 2025 to 2031. This steady growth is driven by cyclical seasonal influenza outbreaks, reinforced public health policies, and rising consumer awareness of preventive healthcare and home testing.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5226086/influenza-a-b-virus-detection-kit
Product Definition: Three Technology Platforms for Different Use Cases
The Influenza A-B Virus Detection Kit is an in vitro diagnostic (IVD) product that specifically identifies influenza A and/or B virus infection from respiratory specimens (nasopharyngeal swabs, nasal swabs, throat swabs, or saliva). The market is characterized by three distinct technology platforms with different performance characteristics and use case suitability.
Antigen Test (Rapid Diagnostic Test / Lateral Flow Immunoassay):
- Technology: Sandwich immunoassay on nitrocellulose membrane; specimen migrates across membrane, binds labeled antibodies specific to influenza A or B nucleoprotein, produces visible color line at test zone.
- Time-to-Result: 10–15 minutes.
- Sensitivity: 50–80% (depending on viral load, specimen quality, brand).
- Specificity: 95–99%.
- Use Cases: Point-of-care settings (clinics, emergency departments, pharmacies), home testing, outbreak screening in schools/workplaces.
- Advantages: No instrument required, lowest cost (USD 2–8 per test), simple to perform, stable at room temperature.
- Disadvantages: Lower sensitivity — false negatives common in low viral load (early infection, poor swab technique).
Nucleic Acid Amplification Testing (NAAT, Including Real-Time PCR):
- Technology: Reverse-transcription polymerase chain reaction (RT-PCR) amplifying influenza A (targeting matrix protein or hemagglutinin gene) and influenza B (targeting hemagglutinin or neuraminidase gene) RNA; real-time fluorescence detection.
- Time-to-Result: 45–120 minutes (lab-based), 30–60 minutes (rapid PCR point-of-care).
- Sensitivity: 95–99%.
- Specificity: 98–100%.
- Use Cases: Hospital laboratories, reference labs, diagnostic confirmation after positive antigen test, surveillance testing.
- Advantages: Gold standard for sensitivity/specificity, can subtype influenza A (seasonal H1N1, H3N2, avian H5N1, H7N9), can include multiplex (simultaneous detection of influenza A/B, RSV, SARS-CoV-2, and other respiratory viruses).
- Disadvantages: Requires instrument (thermocycler), trained personnel, higher cost (USD 15–50 per test), longer turnaround.
Others (Molecular POC / Isothermal Amplification):
- Technology: Isothermal amplification (LAMP, NEAR, nicking enzyme) without thermal cycling; portable instruments.
- Time-to-Result: 15–30 minutes.
- Sensitivity: 85–95%.
- Use Cases: Urgent care centers, physician offices, decentralized testing sites.
- Advantages: Better sensitivity than antigen with modest instrument cost (USD 2,000–10,000), less operator training than PCR, quicker result.
- Disadvantages: Higher consumable cost than antigen (USD 15–25), instrument required.
Market Segmentation: Technology and End-User Channel
The Influenza A-B Virus Detection Kit market is segmented below by technology type and end-user setting, reflecting differences in accuracy requirements, turnaround time expectations, and cost sensitivity.
Segment by Technology Type
- Antigen Test (Lateral Flow): Largest segment by unit volume (estimated 65–70% of test volume) but lower revenue share (35–40%) due to lower price per test. Antigen test sales are highly seasonal, peaking during Northern Hemisphere influenza season (November–March) and Southern Hemisphere season (May–September). Supply chain must accommodate extreme demand spikes.
- Nucleic Acid Amplification Testing (PCR and Multiplex): Smaller unit volume (20–25%) but higher revenue share (45–50%) due to price premium (3–6 times antigen test price). Growth driver: multiplex panels combining influenza A/B, RSV, and SARS-CoV-2 (post-pandemic, consolidated respiratory testing reduces labor cost per patient — run one panel instead of three separate tests).
- Others (Isothermal POC): Smallest segment (5–10%) but fastest-growing due to convenience/performance trade-off.
Segment by End-User Setting
- Hospital (Central Laboratories and Emergency Departments): Largest segment (45–50% revenue share). Hospitals perform both PCR confirmation and antigen screening (rapid triage). Purchasing decisions driven by lab throughput needs, instrument compatibility (PCR platforms already in lab). Larger hospitals run influenza PCR on same instrument and workflow as COVID-19 PCR — multiplex panel adoption high.
- Clinic (Physician Offices, Urgent Care, Community Health Centers): Second-largest segment (30–35% revenue share). Clinics favor antigen or molecular POC tests (quick results while patient waits). Positive influenza result enables immediate antiviral prescribing (oseltamivir baloxavir), improving outcomes if started within 48 hours of symptom onset. Since COVID-19, clinics have adopted more molecular POC instruments (Cepheid GeneXpert, Abbott ID Now) and multiplex testing.
- Others (Pharmacies, Home Testing, Public Health Surveillance): Growing segment (15–20%). Home testing: FDA has authorized over-the-counter influenza A/B home tests (Lucira single-use PCR, now Pfizer-owned), though adoption lower than COVID-19 home tests. Pharmacy-based testing: pharmacists collect swab, run rapid test, prescribe (in states with test-to-treat pharmacy authority). Public health surveillance: WHO Global Influenza Surveillance and Response System (GISRS), national influenza centers, reference labs for strain typing.
Industry Deep Dive: Production Scale, Market Drivers, and Challenges
Production Scale and Margins: In 2024, global production capacity of influenza A-B virus detection kits is estimated at 420 million tests, with sales around 340 million tests (80–85% capacity utilization, reflecting seasonal demand spikes requiring excess capacity). Average price is approximately USD 4.5 per test, with industry gross margin around 62% — attractive but lower than COVID-19 testing margins during pandemic peak. Antigen test gross margins typically 50–60%; PCR test gross margins 65–75%.
Market Drivers:
- Cyclical Seasonal Influenza Outbreaks: Annual influenza epidemics (October–April Northern Hemisphere, April–October Southern Hemisphere) drive predictable demand spikes. Severity varies by season (H3N2-dominant seasons generally more severe). Manufacturers must manage inventory across the year and across hemispheres.
- Multiplex Combination Testing (Influenza + COVID-19 + RSV): Since the COVID-19 pandemic, many countries have integrated influenza testing into routine respiratory infection screening programs and enhanced epidemic prevention systems. Combined detection of influenza, COVID-19, and RSV has emerged as a new growth driver. Single test reporting results for all three viruses reduces lab workload, simplifies clinician decision-making, and provides complete acute respiratory infection picture. Multiplex PCR panels (BioFire FilmArray, Cepheid Xpert Xpress, Roche cobas Liat) cannot be replaced by syndromic testing.
- Expanded Access to Rapid Testing: The rapid penetration of medical institutions and retail pharmacy channels has significantly increased accessibility and adoption of rapid test kits in primary care and home-use scenarios. Test-to-treat programs (pharmacist testing and prescribing) reduce barriers to antiviral therapy.
Market Challenges:
- Product Homogeneity and Price Competition: Antigen tests, in particular, are commoditizing. Many manufacturers (including Chinese producers — Wondfo, Bioperfectus, Biotest, Wantai, Daan Gene, Kehua, Encode) offer comparable performance at competitive prices, compressing profit margins for many manufacturers.
- Supply Chain and Raw Material Volatility: Fluctuating raw material costs (antibodies, nitrocellulose membranes) and international trade barriers threaten supply chain stability, especially for small and medium-sized enterprises. Antibody sourcing is critical; influenza virus strains mutate annually, requiring updated antibodies or primers — regulatory implications (new CE-mark/FDA submission may be required for significant reagent change).
- Regulatory Compliance Across Regions: Complex and time-consuming registration procedures across regions (FDA 510(k) or De Novo in US, CE-IVD under IVDR in Europe, NMPA registration in China) pose compliance and financial challenges. For market access to each major region, required investment per kit (USD 0.5–2 million), clinical studies (hundreds to thousands of specimens). SMEs may need help with multi-region registration costs.
- Consumer Accuracy Expectations: At the same time, consumers’ growing expectations for accuracy and convenience are driving faster product upgrades. Home users expect antigen test accuracy to approach laboratory PCR — not currently achievable. Antigen sensitivity limitations will remain a source of user dissatisfaction and potential liability.
Regional Market and Competitive Landscape
Geographic Distribution: North America (particularly United States) is the largest market, driven by high influenza testing penetration, strong insurance reimbursement for PCR testing, and established retail pharmacy test-to-treat programs. Europe follows, with universal healthcare funding of testing across many countries but lower per-test reimbursement than US. Asia-Pacific is fastest-growing region (China ramping surveillance capacity, India expanding diagnostic access, Japan/South Korea maintain high testing rates due to robust public health systems).
Competitive Landscape — Fragmented with Leading Global Brands and Strong Asian Suppliers:
- Global IVD Leaders: BD (Veritor System), Abbott (ID Now, BinaxNOW), Roche (cobas Liat PCR), Thermo Fisher Scientific (TaqPath PCR).
- Rapid Test Specialists: Quidel (Sofia, QuickVue), Meridian Bioscience, Sekisui Diagnostics, Princeton BioMeditech, Access Bio, Response Biomedical.
- Strong Asian Manufacturers: Guangzhou Wondfo Biotech (China), Jiangsu Bioperfectus Technologies, Hangzhou Biotest Biotech, Wantai BioPharm, Daan Gene, Kehua Bio-Engineering, Zhuhai Encode Medical Engineering.
The presence of many Chinese manufacturers in the global market — particularly for antigen tests — has intensified price competition but also increased global supply capacity during demand surges.
Strategic Implications for Decision-Makers
For diagnostic division executives and testing lab managers, strategic choices depend on setting:
- Hospital Labs: Adopt multiplex PCR panels for respiratory season (influenza, COVID-19, RSV, adenovirus, parainfluenza, human metapneumovirus — single workflow replaces multiple tests). Validate seasonal sensitivity updates (manufacturers switch primer/probe sets annually based on WHO strain recommendations).
- Urgent Care / Pharmacy: Evaluate molecular POC instruments (Cepheid GeneXpert, Abbott ID Now) for improved sensitivity in single-use cartridge format. Antigen tests remain low-cost option for cost-sensitive clinics, but higher false-negative rate can lead to missed influenza cases and inappropriate antibiotic prescribing, antiviral omission.
- Public Health Surveillance: Traditional PCR required for strain identification and antiviral resistance monitoring (neuraminidase inhibitor resistance markers). Pooled testing can extend surveillance capacity during peak season.
For investors, the influenza testing market (4.9% CAGR) is steady but not explosive. Key growth catalysts to monitor: (1) multiplex respiratory panel adoption replacing single-analyte testing, (2) home-use expansion (FDA OTC authorization for additional brands), (3) test-to-treat program expansion (more states allow pharmacist testing, prescribing). Downside risks include lower-than-average influenza season severity (reduces test demand), at-home antigen test price compression (private label, store brand penetration), and new respiratory viruses requiring different testing strategies (avian influenza H5N1 outbreak, if H2H transmission emerges, would increase testing demand but also shift market). Overall, despite structural pressures, the market retains solid long-term potential, supported by continuous technological innovation, stronger brand differentiation, and global market expansion.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
